ML218, >= 98%( HPLC )

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

ML218 has been used as a: T-type channel blocker to test its effect on the nociceptive behavior associated with homocysteinemia ratsT-type voltage-sensitive calcium channel (VSCC) inhibitor in osteoblastsT-type calcium channel blocker to test its effect on the viability of neural progenitor cells

Biochem/physiol Actions

ML218 (CID 45115620) is a potent and selective T-Type (Cav3.1, Cav3.2, Cav3.3) calcium channel inhibitor (Cav3.2, IC50 = 150 nM in Ca2+ flux; Cav3.2 IC50 = 310 nM and Cav3.3 IC50 = 270 nM with good Drug metabolism/Pharmacokinetics. In a panel of 68 GPCRs, ion channels and transporters, ML218 was found to bind significantly only two other targets (sodium channel site 2 and sigma 1) and had no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. It showed robust inhibition of calcium current in STN neurons and was orally active in a rodent model of Parkinson’s Disease.

Features and Benefits

This compound is featured on the Calcium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

5, 25 mg in glass bottle